CL2018002769A1 - Composiciones y métodos recombinantes de inmunoglobulina intravenosa (rlvig) para producción y uso. - Google Patents

Composiciones y métodos recombinantes de inmunoglobulina intravenosa (rlvig) para producción y uso.

Info

Publication number
CL2018002769A1
CL2018002769A1 CL2018002769A CL2018002769A CL2018002769A1 CL 2018002769 A1 CL2018002769 A1 CL 2018002769A1 CL 2018002769 A CL2018002769 A CL 2018002769A CL 2018002769 A CL2018002769 A CL 2018002769A CL 2018002769 A1 CL2018002769 A1 CL 2018002769A1
Authority
CL
Chile
Prior art keywords
compositions
rlvig
intravenous immunoglobulin
production
proteins
Prior art date
Application number
CL2018002769A
Other languages
English (en)
Inventor
Yen-Ming Hsy
Jeng-Shin Lee
Hsiu-Ching Chang
Original Assignee
Ab biosciences inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab biosciences inc filed Critical Ab biosciences inc
Publication of CL2018002769A1 publication Critical patent/CL2018002769A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSICIONES DE PROTEÍNAS DE INMUNOGLOBULINA INTRAVENOSA RECOMBINANTE (RIVIG) Y MÉTODOS PARA PURIFICACIÓN Y USO DE PROTEÍNAS RIVIG, DONDE DICHAS PROTEÍNAS SON ÚTILES COMO MOLÉCULAS INMUNOMODULADORAS PARA EL TRATAMIENTO DE TRASTORNOS INMUNES. ADICIONALMENTE, LA PRESENTE INVENCIÓN PROPORCIONA PROTEÍNAS RIVIG DE ORIGEN NO HUMANO, PARA USO EN TRASTORNOS INMUNITARIOS VETERINARIOS.
CL2018002769A 2016-03-30 2018-09-28 Composiciones y métodos recombinantes de inmunoglobulina intravenosa (rlvig) para producción y uso. CL2018002769A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662315483P 2016-03-30 2016-03-30

Publications (1)

Publication Number Publication Date
CL2018002769A1 true CL2018002769A1 (es) 2018-12-28

Family

ID=59965144

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002769A CL2018002769A1 (es) 2016-03-30 2018-09-28 Composiciones y métodos recombinantes de inmunoglobulina intravenosa (rlvig) para producción y uso.

Country Status (18)

Country Link
US (2) US11304994B2 (es)
EP (1) EP3436484A4 (es)
JP (1) JP7075100B2 (es)
KR (1) KR102477536B1 (es)
CN (1) CN109312000A (es)
AU (1) AU2017245143B2 (es)
BR (1) BR112018070022A2 (es)
CA (1) CA3019530A1 (es)
CL (1) CL2018002769A1 (es)
CO (1) CO2018011457A2 (es)
EA (1) EA201891999A1 (es)
IL (1) IL261968A (es)
MA (1) MA44517A (es)
MX (1) MX2018011865A (es)
SG (1) SG11201808541VA (es)
TW (1) TWI801336B (es)
WO (1) WO2017172853A1 (es)
ZA (1) ZA201806767B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004550A (zh) 2017-12-14 2020-11-27 康诺贝林伦瑙有限公司 用于治疗视神经脊髓炎的重组IgG Fc多聚体
EP3863673A4 (en) * 2018-10-11 2023-01-11 Momenta Pharmaceuticals, Inc. TREATMENT WITH HIGHLY SIALYLATED IGG COMPOSITIONS
MX2021004313A (es) * 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
CN109793894A (zh) * 2019-04-03 2019-05-24 长春西诺生物科技有限公司 犬免疫球蛋白在制备犬溶血性贫血药物中的应用
US20220332847A1 (en) 2019-09-13 2022-10-20 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS
CN112899301B (zh) * 2021-01-29 2023-04-11 中国热带农业科学院热带生物技术研究所 一种木薯普通花叶病毒诱导的基因沉默***及其应用
CN117964777A (zh) * 2021-08-26 2024-05-03 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010001A1 (fr) * 1997-08-21 1999-03-04 Takara Shuzo Co., Ltd. Agents cancerostatiques
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
US7511121B2 (en) 2001-03-09 2009-03-31 Arnason Barry G W Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
US7279329B2 (en) 2005-10-17 2007-10-09 Industrial Technology Research Institute Expression system for producing collagen
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
US20080260738A1 (en) 2007-04-18 2008-10-23 Moore Margaret D Single chain fc, methods of making and methods of treatment
CN101802197A (zh) * 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法
CN107011445B (zh) * 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
DK2598533T3 (en) * 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
EP2561888A1 (en) 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
BR112015001390B1 (pt) * 2012-07-26 2024-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina
BR112015003459A2 (pt) 2012-08-20 2017-09-26 Gliknik Inc moléculas com atividade de ligação ao antígeno e de ligação ao receptor fc gama polivalente
CN104870055A (zh) 2012-10-17 2015-08-26 利物浦热带医学院 免疫调节蛋白
US9637534B2 (en) 2013-03-13 2017-05-02 Genzyme Corporation Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
EP3131926A1 (en) * 2014-04-16 2017-02-22 UCB Biopharma SPRL Multimeric fc proteins
CN108289928A (zh) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途

Also Published As

Publication number Publication date
SG11201808541VA (en) 2018-10-30
IL261968A (en) 2018-10-31
JP2019513024A (ja) 2019-05-23
MX2018011865A (es) 2019-03-28
JP7075100B2 (ja) 2022-05-25
KR20180132731A (ko) 2018-12-12
US20220233658A1 (en) 2022-07-28
WO2017172853A1 (en) 2017-10-05
CN109312000A (zh) 2019-02-05
CO2018011457A2 (es) 2019-02-08
AU2017245143B2 (en) 2024-01-11
AU2017245143A1 (en) 2018-10-18
TW201741335A (zh) 2017-12-01
TWI801336B (zh) 2023-05-11
EP3436484A1 (en) 2019-02-06
US11304994B2 (en) 2022-04-19
ZA201806767B (en) 2023-04-26
BR112018070022A2 (pt) 2019-02-05
CA3019530A1 (en) 2017-10-05
US20190111115A1 (en) 2019-04-18
EP3436484A4 (en) 2019-12-04
KR102477536B1 (ko) 2022-12-13
EA201891999A1 (ru) 2019-08-30
US11801286B2 (en) 2023-10-31
MA44517A (fr) 2019-02-06

Similar Documents

Publication Publication Date Title
CL2018002769A1 (es) Composiciones y métodos recombinantes de inmunoglobulina intravenosa (rlvig) para producción y uso.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CY1123642T1 (el) Αντισωματα enanti-pd-1
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1122948T1 (el) 1η-πυρρολο[2,3-c]πυριδιν-7(6η)-ονες και πυραζολο[3,4-c]πυριδιν-7(6η)-ονες ως αναστολεις των βετ πρωτεϊνων
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
CL2016001968A1 (es) Proteinas de fusion de interleucina-2 y usos de las mismas
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
MX2016001555A (es) Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
BR112016023517A2 (pt) produção de células t projetadas por transpóson sleeping beauty acoplado com seleção de metotrexato
BR112017025574A2 (pt) composições e métodos para degradação de proteínas de má dobra
TN2017000025A1 (en) Anti-lag3 antibodies and antigen-binding fragments.
CL2015002655A1 (es) Moduladores de p2x7
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CY1124360T1 (el) Αντισωματα aντι-il-33 και χρησεις αυτων
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
MX2018007304A (es) Composiciones de interleucina-15 y sus usos.
MX2017003211A (es) Anticuerpos anti-met y composiciones.